Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Gaughan

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
CNS Oncology|October 17, 2017
Regression of an intramedullary spinal cord metastasis with a checkpoint inhibitor: a case reportKester A Phillips, Elizabeth Gaughan, Alejandro Gru, et al.
The American Journal of Dermatopathology|July 19, 2017
Primary Cutaneous Small/Medium CD4+ T-CELL Lymphoproliferative Disorder Occurring in a Patient With Metastatic MelanomaJonathan J Davick, Elizabeth Gaughan, Megan Barry, et al.
JAMA Ophthalmology|July 12, 2019
Bilateral Mydriasis and Serous Retinal Detachments Associated With Ipilimumab and 6-Melanoma Helper Peptide Vaccine for Cutaneous MelanomaChristina Rodriguez, Rebecca Sieburth, Steven Newman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2018
Collaboration Between Rheumatology and Oncology in Immune Checkpoint Inhibitor TherapyDonald L Kimpel, Janet E Lewis, Elizabeth Gaughan, et al.
Immunotherapy|May 4, 2016
Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumorsRyan Gentzler, Richard Hall, Paul R Kunk, et al.
Breast Cancer Research and Treatment|May 20, 2014
Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancersNadine Tung, Elizabeth Gaughan, Michele R Hacker, et al.
JCO Oncology Practice|August 12, 2020
Genesis of Quality Measurements to Improve the Care Delivered to Patients With Brain MetastasesJulio Silvestre, Tracey Gosse, Paul Read, et al.
Cancer Reports (Hoboken, N.J.)|January 8, 2024
Comparing the rate of immunotherapy treatment change due to toxicity by sexKevin J Chua, Shane Kronstedt, Alain Kaldany, et al.
Breast Cancer Research and Treatment|February 6, 2013
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?Steven A Narod, Kelly Metcalfe, Henry T Lynch, et al.
Journal for Immunotherapy of Cancer|August 20, 2021
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanomaSapna P Patel, Gina R Petroni, Jason Roszik, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
CNS Oncology|October 17, 2017
Regression of an intramedullary spinal cord metastasis with a checkpoint inhibitor: a case reportKester A Phillips, Elizabeth Gaughan, Alejandro Gru, et al.
The American Journal of Dermatopathology|July 19, 2017
Primary Cutaneous Small/Medium CD4+ T-CELL Lymphoproliferative Disorder Occurring in a Patient With Metastatic MelanomaJonathan J Davick, Elizabeth Gaughan, Megan Barry, et al.
JAMA Ophthalmology|July 12, 2019
Bilateral Mydriasis and Serous Retinal Detachments Associated With Ipilimumab and 6-Melanoma Helper Peptide Vaccine for Cutaneous MelanomaChristina Rodriguez, Rebecca Sieburth, Steven Newman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2018
Collaboration Between Rheumatology and Oncology in Immune Checkpoint Inhibitor TherapyDonald L Kimpel, Janet E Lewis, Elizabeth Gaughan, et al.
Immunotherapy|May 4, 2016
Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumorsRyan Gentzler, Richard Hall, Paul R Kunk, et al.
Breast Cancer Research and Treatment|May 20, 2014
Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancersNadine Tung, Elizabeth Gaughan, Michele R Hacker, et al.
JCO Oncology Practice|August 12, 2020
Genesis of Quality Measurements to Improve the Care Delivered to Patients With Brain MetastasesJulio Silvestre, Tracey Gosse, Paul Read, et al.
Cancer Reports (Hoboken, N.J.)|January 8, 2024
Comparing the rate of immunotherapy treatment change due to toxicity by sexKevin J Chua, Shane Kronstedt, Alain Kaldany, et al.
Breast Cancer Research and Treatment|February 6, 2013
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?Steven A Narod, Kelly Metcalfe, Henry T Lynch, et al.
Journal for Immunotherapy of Cancer|August 20, 2021
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanomaSapna P Patel, Gina R Petroni, Jason Roszik, et al.
Pageof 2